NON-HDLC AND AIP COMPARED TO HS-CRP IN HYPERTRIGLYCERIDEMIC DIABETICS – A BETTER
Abstract
Diabetic dyslipidemia is a modifiable risk factor of cardiovascular disease, characterized by elevated triglycerides, presence of small dense LDL-C particles and decreased HDL-C. Non-HDL-C is considered to be a measure of apo B containing atherogenic lipoproteins and a better predictor of CVD in type 2 DM. The aim of this study is to compare Non-HDL-C and Atherogenic Index of Plasma (AIP) in 120 type 2 diabetic subjects and correlate with hs-CRP, a low grade systemic inflammatory marker to assess the cardiovascular risk.
On comparison, Non-HDL-C an easily calculated parameter than AIP showed a statistically significant value and correlated more significantly with hs-CRP in hypertriglyceridemic type 2 diabetic subjects. Thus, Non-HDL-C is considered to be a simple, cost-effective calculated tool and a better representative of triglyceride rich lipoprotein that can assess diabetic dyslipidemia and considered to be a better predictor of adverse cardiovascular events.
Keywords: Non-HDL-C, Atherogenic Index of Plasma (AIP), high sensitive - C Reactive protein.
Downloads
References
Gupta O.P., Phatak S. Rev article. 2003; 23 (2), 37 – 50.
Liu J, Sempons C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint contribution of non-HDLc and LDLc and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes care. 2005; 28: 1916 – 1921.
Chih-yuan wang and Tien-Chun Chang. Non-HDL cholesterol is reliable to be an early predictor for vascular inflammation in type 2 diabetes mellitus. J of Clin. Endocrinol. Met. 2004; 89(9): 4762 – 4767.
Poonguzhali.D.V, Vinodhini.V. M. Ebenezer William.W, Kumar.J.S. Evaluation of apolipoprotein-B levels in dysglycemia. Asian J Pharm Clin Res.2013; 6(3): 112 – 114.
Tan HM, Johns D, Bradly Glazer N. Pioglitazone reduces an Atherogenic Index of plasma in patients with type 2 diabetes mellitus. Clin Chem. 2004; 50: 1184 – 1188.
Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and American College of Cardiology Foundation. Diabetes Care. 2008; 31: 811 – 822.
Dobiasova M. Atherogenic Index of Plasma (log TG/HDL): theoretical and practical implications. Clin Chem. 2004; 50: 1113 – 1115.
Koenig W. Predicting risk and treatment benefit in atherosclerosis: the role of C- reactive protein. Internat J Cardiol. 2005; 98(2): 100 – 206.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application of clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499 – 511.
Arul Senghor KA, Ebenezer William W, Jeevanathan N. Non-HDLc compared to direct LDLc in Diabetic patients with hypertiglyceridemia. International journal of Science Innovations and Discoveries. 2012; 3(1): 51 – 55.
Lu W, Resnick HE, Jablonski KA, Jones KL et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care. 2003; 26: 16 – 23.
The expert Panel: Third report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of high blood cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002; 106: 3143 – 3421.
Lamarche B, Despres JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular study. Am J Cardiol. 1995; 75: 1189 – 1195.
David M. Capuzzi, Jeffrey S. Freeman. C- Reactive protein and cardiovascular disease in Metabolic syndrome and type 2 diabetes: controversy and challenge. Clinical Diabetes. 2007; 25(1): 16 – 22.
Samia Mora, Paul M Ridker. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) – Can C-reactive Protein be used to Target Statin Therapy in Primary Prevention?Am J Cardiol. 2006; 97: 33A – 41A.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.